Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SABBOBCATon Jan 26, 2021 9:02am
143 Views
Post# 32385679

Dress for the job you want

Dress for the job you wantIn the US, Large Accelerated Filers must file year end financials within 60 days. THTX was a Large Accelerated Filer, but when the market cap fell below US$560M, they got dropped to Accelerated Filer rules which gives them 75 days to file. There is no rule saying they can't take the full 75 days, but yet again the company is showing they aren't ready or willing to do what is needed to play with the big dogs. If management believes the company is worth > US$1B then they should act like it and show the market they can do the basic functions required to deserve that valuation. I acknowledge that this raise has complicated that timeline, but that was self inflicted. Dubuc again has shown that he is not the man for the job. We need a CFO that can dress the company for the valuation we all want, not the valuation we have.
<< Previous
Bullboard Posts
Next >>